

## Is It Time to Embrace the Caffeine Level?

We thank Dr Eichenwald and the American Academy of Pediatrics for their report, "Apnea of Prematurity."<sup>1</sup> Working in a large 84-bed level IV NICU, we have seen firsthand the impact that an Apnea and Bradycardia Guideline can have on length of stay (LOS), parent and staff satisfaction, and other outcomes. Since we introduced our Apnea and Bradycardia Guideline 2 years ago, we have seen a reduction in our very low birth weight LOS by 24% (Vermont Oxford Network [VON] database), which we attribute in part to standardization of what we consider clinically significant events, and how we manage these events. Although the definition of apnea is not evidence based and considerable variability exists in the literature, we question the definition of an apneic spell as defined by Dr Eichenwald—cessation of breathing of >20 seconds or heart rate of <100 beats per minute when accompanied by cessation of breathing <20 seconds—because most sources define bradycardia in this situation as <80 beats per minute (and even lower at higher gestational ages). These sources also cite a minimum time period during which a bradycardic event needs to occur to be considered significant. A higher heart rate and/or lower event duration threshold may lead to unnecessary prolonged observation in the hospital for a physiologic and benign condition.

We are aware of the literature suggesting caffeine level monitoring is unnecessary because caffeine has a wide therapeutic index for the treatment of apnea of prematurity.<sup>2</sup> Our experience is that levels in the upper normal therapeutic range (15–20 mcg/mL) yield a greater response, especially for very low birth weight neonates, and that caffeine level monitoring is essential to attain these desired levels because caffeine clearance is variable. Our findings coincide with those of Dr Gal, who demonstrated a proportional caffeine

level to apnea of prematurity response relationship (even for levels 40+ mcg/mL).<sup>3</sup> Also, some studies admit to failing to reach therapeutic levels with standard caffeine dosing, and these same studies suggest a dose-response relationship with higher levels achieving greater efficacy.<sup>2</sup> There is also evidence correlating caffeine concentration maintenance above 14.5 mcg/mL with reduced chronic lung disease rates in neonates ≤29 weeks postmenstrual age.<sup>4</sup> We continue to report chronic lung disease rates in the best VON quartile (VON database), which we attribute, in part, to maintenance of caffeine levels in the upper normal therapeutic range.

Another concern recently raised is that a significant number of infants do not have subtherapeutic caffeine levels (defined as <5 mcg/mL) 7 days after discontinuation of caffeine (the number of days often cited in the literature at which an infant can safely be discharged off caffeine), and many of these infants continue to have pathologic apnea.<sup>5</sup> A benefit of obtaining caffeine levels after discontinuation of caffeine before discharge would be for calculation or estimation of patient-specific pharmacokinetic parameters to be used for prediction of subtherapeutic levels to help ensure safer discharge.<sup>5</sup> We feel that this new practice will decrease the risk of patients developing postdischarge hypoxic or apneic events and possibly decrease the likelihood of readmissions for these serious events.

Doron J. Kahn

Neonatologist, Assistant Medical Director, Joe DiMaggio Children's Hospital, Hollywood, Florida  
E-mail: dkahn@mhs.net

Robert Godin

Clinical Specialist, Pharmacist

**POTENTIAL CONFLICT OF INTEREST:** The authors have indicated they have no potential conflicts of interest to disclose.

### REFERENCES

1. Eichenwald EC; Committee on Fetus and Newborn. Apnea of prematurity. *Pediatrics*. 2016;137(1):1–7

2. Natarajan G, Botica ML, Thomas R, Aranda JV. Therapeutic drug monitoring for caffeine in preterm neonates: an unnecessary exercise? *Pediatrics*. 2007; 119(5):936–940
3. Gal P. Caffeine therapeutic drug monitoring is necessary and cost-effective. *J Pediatr Pharmacol Ther*. 2007;12(4):212–215
4. Alur P, Bollampalli V, Bell T, Hussain N, Liss J. Serum caffeine concentrations and short-term outcomes in premature infants of ≤29 weeks of gestation. *J Perinatol*. 2015; 35(6):434–438
5. Doyle J, Davidson D, Katz S, Varela M, Demeglio D, DeCristofaro J. Apnea of prematurity and caffeine pharmacokinetics: potential impact on hospital discharge. *J Perinatol*. 2016;36(2):141–144

doi:10.1542/peds.2016-0403A

## Response From Committee on Fetus and Newborn

We thank Drs Kahn and Godin for their thoughtful comments on the American Academy of Pediatrics Clinical Report on Apnea of Prematurity.<sup>1</sup> We agree, as outlined in the clinical report, that individual NICUs should develop guidelines for monitoring of infants at risk for apnea of prematurity (including alarm limits), as well as policies and procedures for caregiver assessment, intervention, and documentation of apnea/bradycardia/desaturation events as well as the duration of the period of observation before discharge. As reported by Drs Kahn and Godin, development of such a clinical guideline regarding apnea of prematurity and its management was associated with a lower length of stay of very low birth weight infants in their NICU. Although it is difficult to attribute all of the decrease in length of stay to the apnea guideline, it does amplify the importance of consistency among providers around discharge planning for infants with apnea of prematurity.

Our definition of an apneic spell included the oft-cited duration of apnea for >20 seconds associated with

## Is It Time to Embrace the Caffeine Level?

Doron J. Kahn and Robert Godin

*Pediatrics* 2016;137;

DOI: 10.1542/peds.2016-0403A originally published online April 29, 2016;

### Updated Information & Services

including high resolution figures, can be found at:  
<http://pediatrics.aappublications.org/content/137/5/e20160403A>

### References

This article cites 5 articles, 2 of which you can access for free at:  
<http://pediatrics.aappublications.org/content/137/5/e20160403A#BIBL>

### Subspecialty Collections

This article, along with others on similar topics, appears in the following collection(s):  
**Administration/Practice Management**  
[http://www.aappublications.org/cgi/collection/administration:practice\\_management\\_sub](http://www.aappublications.org/cgi/collection/administration:practice_management_sub)

### Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:  
<http://www.aappublications.org/site/misc/Permissions.xhtml>

### Reprints

Information about ordering reprints can be found online:  
<http://www.aappublications.org/site/misc/reprints.xhtml>

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™



# PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

## **Is It Time to Embrace the Caffeine Level?**

Doron J. Kahn and Robert Godin

*Pediatrics* 2016;137;

DOI: 10.1542/peds.2016-0403A originally published online April 29, 2016;

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://pediatrics.aappublications.org/content/137/5/e20160403A>

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2016 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 1073-0397.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™

